article thumbnail

Bridging the healthcare digital divide: a gradual approach to adopting ePI

European Pharmaceutical Review

They are vital to ensuring the safe and effective use of medicines, making them an integral part of healthcare in Europe. 3 Moreover, digital platforms can be tailored to the needs of patients and healthcare professionals, offering accessible, trustworthy and up-to-date information on medicines precisely when required.

article thumbnail

W. Va. judge sides with drug distributors in bellwether opioid trial

MedCity News

From 2001 to 2017, the fatal overdose rate in Cabell County increased from 16.6 per 100,000. Judge finds no evidence of causation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Psychedelic medicines: are they gaining traction in Europe?

European Pharmaceutical Review

For example, the relaxed attitude towards cannabis in the Netherlands is well-known and Portugal has decriminalised the possession and consumption of all illicit substances since 2001. However, some similar activity is being seen this side of the channel.

Medicine 118
article thumbnail

Jim Lefevere

Pharma Marketing Network

Jim Lefevere is an award-winning highly-influential agile intrapreneur with over 20 years of expertise in the consumer goods, startups, medical device, and healthcare industries. Jim has enjoyed a very diverse and successful career with progressive growth in leadership, global marketing, digital marketing, and strategy development.

Media 52
article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

Chris was named a ‘Rising Star’ in the 2022 Legal 500 Rankings for Life Sciences and Healthcare. Information guide for healthcare professionals, EMA and EU Commission updated 2/10/2019. Directive 2001/83 (as amended). References/Endnotes. Biosimilars in the EU.

article thumbnail

Pharma-biotech dealmaking incentives shift amid a continued drought in financing

Clarivate

What do the years 2001, 2007, 2014, and 2022 have in common? These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. In short, the biotech bubble had burst.

Pharma 52
article thumbnail

PM360 Announces 2023 Trailblazer Award Finalists

PM360

Each of their trailblazing efforts result in much more than personal or organization success, it results in better quality of life for patients, better care options for healthcare providers, and happier and healthier people around the world.” Dermavant Sun Pharmaceutical Industries Ltd.